InvestSMART

Starpharma Holdings Limited (ASX:SPL)

ALERT: Price-sensitive ASX Announcement for SPL
Current share price for SPL : $0.800 0.045 (5.96%)+
Announcement
Release
15 Jul 2026 9:03AM
Price at Release
$0.755
Full Release
download
Summary
Starpharma Holdings Limited's Quarterly Activities Report and Appendix 4C for the quarter ended 30 June 2026 highlights significant advancements in their DEP® platform, particularly the DEP® HER2-Lu program, which is moving towards a first-in-human Phase 1 study. The report underscores progress in preclinical data, strategic partnerships, and patent applications, enhancing its radiopharmaceutical applications. Financially, the company reported a cash balance of $11.0 million at the end of the quarter. Key milestones include a collaboration with Radiopharm Theranostics and notable market activities with products like Viraleze™ and VivaGel® BV, supporting revenue growth and potential future developments in oncology treatments.
Key Points
  • Completion of DEP® HER2-Lu preclinical data package and GMP dendrimer manufacture.
  • Filing of new patent application for DEP® technology in radioligand therapy.
  • Milestone achievement with Radiopharm Theranostics, triggering a $0.5 million option fee.
  • Cash balance of $11.0 million as of 30 June 2026.
  • Significant partner engagement at the BIO International Convention.
  • DEP® HER2-Lu advancement towards first-in-human clinical study.
  • Strong engagement with strategic partners Genentech and Petalion.
  • Increased Viraleze™ sales by approximately 50% compared to FY25.
  • Ongoing discussions for VivaGel® BV distribution expansion in Europe.
  • Financial summary indicates reduced net operating cash outflows for FY26.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.